Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Frostman who wrote (8065)	5/14/1998 12:11:00 PM
From: Sal Milani	Read Replies (1) \| Respond to of 23519

I copied the Sweden news from Yahoo at 9:09Am EST. Release time was 7:31 AM EST. Sal

To: Frostman who wrote (8065)	5/14/1998 12:11:00 PM
From: E'Lane	Respond to of 23519

[From Yahoo] Thursday May 14, 7:31 am Eastern Time Company Press Release VIVUS' MUSE Now Approved in Sweden MOUNTAIN VIEW, Calif.--(BW HealthWire)--May 14, 1998--VIVUS Inc. (NASDAQ:VVUS - news) today announced that its lead product, MUSE(R) (alprostadil) has been approved by the Medical Products Agency (MPA), a division of the Swedish Pharmacopoeia Commission, for sale and distribution by Astra AB [NYSE:A - news] in Sweden. MUSE is currently cleared for commercial distribution and has been launched in the United States and the United Kingdom. Approvals have also been received and launches are pending in Argentina, Brazil, South Korea and Switzerland. Astra AB and Janssen Pharmaceutica will distribute and market the product outside the United States and VIVUS will be the exclusive producer of MUSE for domestic and international markets from its manufacturing facilities in Lakewood, New Jersey. ''VIVUS is aggressively pursuing approvals of MUSE in international marketplaces with a goal of making MUSE available around the globe. A key element of our international strategy is to collaborate with a premier pharmaceutical company in each region of the world. With Astra and Janssen as our marketing partners for MUSE outside the United States we have achieved this goal,'' said Leland Wilson, President and Chief Executive Officer. ''Astra's successful launch of MUSE in the UK is indicative of the broad acceptance by patients and physicians to MUSE to treat erectile dysfunction.'' Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known MUSE(R) (alprostadil). This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra.